Cargando…
Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034
The structures of both native and S139A holo-HCV NS3/4A protease domain were solved to high resolution. Subsequently, structures were determined for a series of ketoamide inhibitors in complex with the protease. The changes in the inhibitor potency were correlated with changes in the buried surface...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
International Union of Crystallography
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394794/ https://www.ncbi.nlm.nih.gov/pubmed/18421139 http://dx.doi.org/10.1107/S0909049507064229 |
_version_ | 1782155451508457472 |
---|---|
author | Madison, Vincent Prongay, Andrew J. Guo, Zhuyan Yao, Nanhua Pichardo, John Fischmann, Thierry Strickland, Corey Myers Jr, Joseph Weber, Patricia C. Beyer, Brian M. Ingram, Richard Hong, Zhi Prosise, Winifred W. Ramanathan, Lata Taremi, S. Shane Yarosh-Tomaine, Taisa Zhang, Rumin Senior, Mary Yang, Rong-Sheng Malcolm, Bruce Arasappan, Ashok Bennett, Frank Bogen, Stephane L. Chen, Kevin Jao, Edwin Liu, Yi-Tsung Lovey, Raymond G. Saksena, Anil K. Venkatraman, Srikanth Girijavallabhan, Viyyoor Njoroge, F. George |
author_facet | Madison, Vincent Prongay, Andrew J. Guo, Zhuyan Yao, Nanhua Pichardo, John Fischmann, Thierry Strickland, Corey Myers Jr, Joseph Weber, Patricia C. Beyer, Brian M. Ingram, Richard Hong, Zhi Prosise, Winifred W. Ramanathan, Lata Taremi, S. Shane Yarosh-Tomaine, Taisa Zhang, Rumin Senior, Mary Yang, Rong-Sheng Malcolm, Bruce Arasappan, Ashok Bennett, Frank Bogen, Stephane L. Chen, Kevin Jao, Edwin Liu, Yi-Tsung Lovey, Raymond G. Saksena, Anil K. Venkatraman, Srikanth Girijavallabhan, Viyyoor Njoroge, F. George |
author_sort | Madison, Vincent |
collection | PubMed |
description | The structures of both native and S139A holo-HCV NS3/4A protease domain were solved to high resolution. Subsequently, structures were determined for a series of ketoamide inhibitors in complex with the protease. The changes in the inhibitor potency were correlated with changes in the buried surface area upon binding the inhibitor to the active site. The largest contributions to the binding energy arise from the hydrophobic interactions of the P1 and P2 groups as they bind to the S1 and S2 pockets. This correlation of the changes in potency with increased buried surface area contributed directly to the design of a potent tripeptide inhibitor of the HCV NS3/4A protease, which is currently in clinical trials. |
format | Text |
id | pubmed-2394794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | International Union of Crystallography |
record_format | MEDLINE/PubMed |
spelling | pubmed-23947942009-03-05 Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034 Madison, Vincent Prongay, Andrew J. Guo, Zhuyan Yao, Nanhua Pichardo, John Fischmann, Thierry Strickland, Corey Myers Jr, Joseph Weber, Patricia C. Beyer, Brian M. Ingram, Richard Hong, Zhi Prosise, Winifred W. Ramanathan, Lata Taremi, S. Shane Yarosh-Tomaine, Taisa Zhang, Rumin Senior, Mary Yang, Rong-Sheng Malcolm, Bruce Arasappan, Ashok Bennett, Frank Bogen, Stephane L. Chen, Kevin Jao, Edwin Liu, Yi-Tsung Lovey, Raymond G. Saksena, Anil K. Venkatraman, Srikanth Girijavallabhan, Viyyoor Njoroge, F. George J Synchrotron Radiat Diffraction Structural Biology The structures of both native and S139A holo-HCV NS3/4A protease domain were solved to high resolution. Subsequently, structures were determined for a series of ketoamide inhibitors in complex with the protease. The changes in the inhibitor potency were correlated with changes in the buried surface area upon binding the inhibitor to the active site. The largest contributions to the binding energy arise from the hydrophobic interactions of the P1 and P2 groups as they bind to the S1 and S2 pockets. This correlation of the changes in potency with increased buried surface area contributed directly to the design of a potent tripeptide inhibitor of the HCV NS3/4A protease, which is currently in clinical trials. International Union of Crystallography 2008-04-18 /pmc/articles/PMC2394794/ /pubmed/18421139 http://dx.doi.org/10.1107/S0909049507064229 Text en © International Union of Crystallography 2008 http://journals.iucr.org/services/termsofuse.html This is an open-access article distributed under the terms described at http://journals.iucr.org/services/termsofuse.html. |
spellingShingle | Diffraction Structural Biology Madison, Vincent Prongay, Andrew J. Guo, Zhuyan Yao, Nanhua Pichardo, John Fischmann, Thierry Strickland, Corey Myers Jr, Joseph Weber, Patricia C. Beyer, Brian M. Ingram, Richard Hong, Zhi Prosise, Winifred W. Ramanathan, Lata Taremi, S. Shane Yarosh-Tomaine, Taisa Zhang, Rumin Senior, Mary Yang, Rong-Sheng Malcolm, Bruce Arasappan, Ashok Bennett, Frank Bogen, Stephane L. Chen, Kevin Jao, Edwin Liu, Yi-Tsung Lovey, Raymond G. Saksena, Anil K. Venkatraman, Srikanth Girijavallabhan, Viyyoor Njoroge, F. George Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034 |
title | Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034 |
title_full | Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034 |
title_fullStr | Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034 |
title_full_unstemmed | Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034 |
title_short | Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034 |
title_sort | key steps in the structure-based optimization of the hepatitis c virus ns3/4a protease inhibitor sch503034 |
topic | Diffraction Structural Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394794/ https://www.ncbi.nlm.nih.gov/pubmed/18421139 http://dx.doi.org/10.1107/S0909049507064229 |
work_keys_str_mv | AT madisonvincent keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT prongayandrewj keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT guozhuyan keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT yaonanhua keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT pichardojohn keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT fischmannthierry keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT stricklandcorey keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT myersjrjoseph keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT weberpatriciac keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT beyerbrianm keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT ingramrichard keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT hongzhi keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT prosisewinifredw keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT ramanathanlata keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT taremisshane keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT yaroshtomainetaisa keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT zhangrumin keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT seniormary keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT yangrongsheng keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT malcolmbruce keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT arasappanashok keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT bennettfrank keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT bogenstephanel keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT chenkevin keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT jaoedwin keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT liuyitsung keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT loveyraymondg keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT saksenaanilk keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT venkatramansrikanth keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT girijavallabhanviyyoor keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 AT njorogefgeorge keystepsinthestructurebasedoptimizationofthehepatitiscvirusns34aproteaseinhibitorsch503034 |